Scrip

CRISPR Therapeutics Moves Into Off-The-Shelf CAR-T Lead, But Durability Test Awaits

Allogene Remains A Rival Despite Safety Hiatus

13 Oct 2021

Some remain unconvinced on durability, but CRISPR Therapeutics is looking at a second ‘consolidation’ dose and other measures to boost CTX110’s efficacy in a pivotal trial.

CRISPR Therapeutics building — CRISPR Therapeutics is set to begin its pivotal trial in early 2022, but must demonstrate durability in order to challenge established autologous CAR-Ts.

CRISPR Therapeutics has unveiled promising early data from its allogeneic CAR-T cell therapy CTX110, putting it into pole position in the obstacle-strewn race to develop the first off-the-shelf treatment for CD19+ B-cell malignancies.

Its Phase I CARBON trial showed a 58% overall response (ORR) rate, a 38% complete response (CR) rate and six-month...